0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fungal Infections Diagnosis Market by Diagnostic Technology, End User, Specimen Type, Pathogen Type, Testing Mode - Global Forecast to 2030- Product Image
Fungal Infections Diagnosis Market by Diagnostic Technology, End User, Specimen Type, Pathogen Type, Testing Mode - Global Forecast to 2030- Product Image
Sale

Fungal Infections Diagnosis Market by Diagnostic Technology, End User, Specimen Type, Pathogen Type, Testing Mode - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5899679
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Fungal Infections Diagnosis Market grew from USD 2.23 billion in 2024 to USD 2.40 billion in 2025. It is expected to continue growing at a CAGR of 6.99%, reaching USD 3.35 billion by 2030.

Navigating the Complex Terrain of Fungal Diagnostics

Fungal infections impose a significant health burden worldwide, challenging clinicians and laboratories to accurately identify diverse pathogens in a timely manner. As invasive mycoses continue to rise among immunocompromised populations, the demand for precise diagnostic solutions has never been greater. In this landscape, delays or inaccuracies in detection can lead to prolonged hospital stays, increased morbidity, and higher healthcare costs. At the same time, traditional culture techniques face limitations in speed and sensitivity, while emerging modalities promise greater accuracy but require validation and integration.

Against this backdrop, stakeholders across the healthcare continuum are seeking a clear understanding of current capabilities, unmet needs, and future directions in fungal diagnostics. This executive summary lays the foundation for comprehending how technological innovations, regulatory developments, and market dynamics converge to shape diagnostic workflows. By highlighting critical trends and identifying pivotal opportunities, this introduction sets the stage for a detailed exploration of transformative shifts, geopolitical influences, segmentation insights, and strategic recommendations that will guide industry leaders toward informed decision making.

Redefining Diagnostics Through Innovation and Collaboration

The fungal diagnostics landscape is undergoing radical transformation, driven by breakthroughs in molecular biology, automation, and data analytics. Laboratories are moving beyond traditional culture-based approaches to embrace rapid immunoassays, mass spectrometry workflows, advanced microscopy techniques, and high-throughput genomic platforms. These shifts are not merely incremental; they represent a paradigm change in which real-time data interpretation, multiplexed testing, and digital integration are redefining diagnostic certainty and clinical decision support.

Concurrently, artificial intelligence and machine learning algorithms are being deployed to analyze complex spectral data from MALDI-TOF MS and to interpret morphological patterns in digital histopathology, enhancing sensitivity while reducing human error. Point-of-care devices are transitioning from concept to clinical reality, bringing near-patient diagnostics into resource-limited settings and streamlining sample-to-answer timelines. In parallel, collaborative networks of academic centers, commercial laboratories, and regulatory bodies are fostering standardization of protocols and accelerating the translation of novel assays into practice. As a result, stakeholders must adapt swiftly to new validation requirements, integration challenges, and shifting reimbursement landscapes to capitalize on these transformative opportunities.

Navigating Trade Dynamics to Safeguard Diagnostic Supplies

Recent adjustments to United States tariff schedules in 2025 have introduced new cost pressures for manufacturers and laboratories dependent on imported reagents, consumables, and diagnostic instruments. The reclassification of certain molecular assay components and high-precision instrumentation under higher duty brackets has led to immediate cost increases, compelling suppliers to reevaluate sourcing strategies and manufacturers to consider onshoring critical production processes. Supply chain diversification has become essential, with regional production hubs emerging to mitigate exposure to broader trade tensions.

Laboratories are experiencing the ripple effects through elevated prices for sequencing kits, PCR reagents, and mass spectrometry consumables, which in turn affect testing budgets and reimbursement negotiations. In response, industry players are engaging in strategic partnerships to establish local manufacturing capabilities, exploring tariff engineering options, and negotiating long-term contracts to stabilize pricing. These efforts are accompanied by heightened advocacy for tariff exemptions on life-saving diagnostic essentials, underscoring the delicate balance between trade policy and public health imperatives.

Unraveling Market Complexity Through Detailed Segmentation

Fungal diagnostics can be understood through multiple lenses that delineate market requirements and adoption patterns. Technologies range from classic culture-based workflows, which include both liquid broth culture systems and solid media plates, to immunoassays utilizing enzyme-linked immunosorbent protocols and lateral flow devices. Mass spectrometry via MALDI-TOF platforms and advanced microscopy techniques complement molecular diagnostics, which encompass next-generation sequencing approaches such as Illumina and Ion Torrent platforms, as well as polymerase chain reaction modalities including conventional and real-time assays. Each diagnostic modality delivers varying levels of sensitivity, turnaround time, and operational complexity, influencing selection criteria for end users.

End users themselves span diagnostic laboratories that demand high-throughput systems, hospitals and clinical settings prioritizing rapid point-of-care results, and research institutes focusing on exploratory pathogen discovery. Specimen types further shape market dynamics, with blood, cerebrospinal fluid, sputum, tissue biopsies, and urine samples each presenting unique preanalytical and workflow considerations. Pathogen-specific segments such as Aspergillosis, Candidiasis, Cryptococcosis, Dermatophytosis, and Mucormycosis reveal disease prevalence patterns that guide assay development priorities. Lastly, testing modes differentiate between laboratory-based protocols, decentralized point-of-care applications, and assays designated solely for research use. Together, these segmentation dimensions illuminate the heterogeneous needs and technological trajectories that define the fungal diagnostics ecosystem.

Mapping Regional Dynamics Driving Market Growth

Regional landscapes exhibit distinct drivers and constraints that shape the trajectory of fungal diagnostics worldwide. In the Americas, robust healthcare infrastructures and well-established reimbursement frameworks support widespread adoption of advanced molecular assays and immunoassays, although cost containment remains a persistent challenge. Stakeholders in North America are actively investing in decentralized testing networks to enhance accessibility in rural and underserved areas.

The Europe, Middle East & Africa region presents a multifaceted picture, with Western Europe leading in regulatory harmonization and adoption of point-of-care devices, while emerging markets in Eastern Europe and North Africa prioritize cost-effective culture-based solutions. Regulatory pathways across this bloc are converging, yet reimbursement and pricing pressures vary significantly between jurisdictions. Meanwhile, the Asia-Pacific region is experiencing the fastest growth, propelled by expanding healthcare access, surging research activity, and growing investments in next-generation sequencing centers. Local manufacturing initiatives and public-private collaborations are accelerating market penetration in key markets such as China, India, Japan, and Australia.

Competitive Landscape Fueled by Innovation and Collaboration

The competitive arena in fungal diagnostics is characterized by rapid innovation, strategic alliances, and agile market positioning. Established in vitro diagnostics firms are expanding their portfolios through targeted acquisitions of niche molecular assay developers, while specialized biotech companies are forging collaborations with mass spectrometry providers to enhance diagnostic breadth. Key players are investing heavily in research and development to refine multiplexed assays capable of simultaneous detection of multiple fungal pathogens, addressing the complexity of co-infections and emerging resistance patterns.

Additionally, contract research organizations are capitalizing on growing demand for assay validation and clinical trial support services, leveraging partnerships with instrument manufacturers to offer end-to-end solutions. Strategic collaborations between reagent suppliers and digital health platforms aim to integrate diagnostic outputs with electronic medical records, enhancing data-driven decision-making. Collectively, these dynamics underscore a market in which integrated solutions and seamless interoperability confer a competitive edge.

Strategic Imperatives to Accelerate Market Leadership

Industry leaders must take decisive steps to capitalize on emerging opportunities within fungal diagnostics. First, investing in modular, scalable molecular platforms will allow rapid adaptation to new pathogen targets and regulatory requirements. Pursuing strategic partnerships with local manufacturers can mitigate tariff-related cost pressures and bolster supply chain resilience. Embracing digital integration-linking diagnostic outputs to clinical decision support systems-will enhance the value proposition for healthcare providers and payers alike.

Moreover, establishing robust training programs for laboratory personnel and clinicians will accelerate uptake of advanced assays, ensuring consistent quality and reducing user errors. Stakeholders should also engage proactively with regulatory authorities to streamline approval pathways and advocate for reduced import tariffs on critical diagnostic reagents. Finally, prioritizing patient-centric product development-focusing on faster time-to-result, portability, and user-friendly interfaces-will drive adoption in both centralized and decentralized settings.

Robust Methodology Underpinning Insightful Analysis

This analysis is grounded in a rigorous research framework that integrates both secondary and primary data sources. An exhaustive review of scientific literature, regulatory filings, company reports, and trade publications provided a baseline for market characterization. This secondary research was complemented by in-depth interviews with key opinion leaders, laboratory directors, and regulatory experts across multiple regions to capture real-world insights on diagnostic workflows and unmet needs.

Data triangulation techniques ensured validation of findings by cross-referencing qualitative inputs with quantitative metrics. A structured questionnaire guided the primary research, supporting consistency and comparability of responses. Segment definitions were refined iteratively, drawing on stakeholder feedback to ensure relevance and clarity. Finally, all data points underwent a thorough quality assurance process, including peer reviews and consistency checks, to uphold the highest standards of analytical accuracy.

Synthesizing Trends to Inform Strategic Action

In summary, the fungal diagnostics market stands at a critical inflection point where technological innovation, regulatory evolution, and geopolitical developments converge. The increasing prevalence of invasive fungal infections demands agile responses from industry participants, including investment in rapid molecular assays, expansion of decentralized testing capabilities, and strategic supply chain realignment. Regional variations in infrastructure, reimbursement, and regulatory environments present both challenges and opportunities for market players.

As competition intensifies, differentiation will hinge on integrated solutions that combine advanced diagnostics with digital interoperability and comprehensive support services. Stakeholders who proactively align their strategies with emerging trends-such as AI-driven analysis, point-of-care expansion, and localized manufacturing-will be well positioned to capture growth and deliver improved patient outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Diagnostic Technology
    • Culture Based
      • Liquid Broth Culture
      • Solid Media Culture
    • Immunoassays
      • Elisa
      • Lateral Flow Assay
    • MALDI TOF MS
    • Microscopy
    • Molecular Diagnostics
      • Next Generation Sequencing
        • Illumina Sequencing
        • Ion Torrent Sequencing
      • Polymerase Chain Reaction
        • Conventional Polymerase Chain Reaction
        • Real Time Polymerase Chain Reaction
  • End User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research Institutes
  • Specimen Type
    • Blood
    • Cerebrospinal Fluid
    • Sputum
    • Tissue
    • Urine
  • Pathogen Type
    • Aspergillosis
    • Candidiasis
    • Cryptococcosis
    • Dermatophytosis
    • Mucormycosis
  • Testing Mode
    • Laboratory Testing
    • Point Of Care Testing
    • Research Use Only
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Roche Holding AG
  • Abbott Laboratories
  • bioMérieux SA
  • Becton, Dickinson and Company
  • Bruker Corporation
  • DiaSorin S.p.A.
  • QIAGEN N.V.
  • Siemens Healthineers AG
  • Fujirebio Holdings, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Fungal Infections Diagnosis Market, by Diagnostic Technology
8.1. Introduction
8.2. Culture Based
8.2.1. Liquid Broth Culture
8.2.2. Solid Media Culture
8.3. Immunoassays
8.3.1. Elisa
8.3.2. Lateral Flow Assay
8.4. MALDI TOF MS
8.5. Microscopy
8.6. Molecular Diagnostics
8.6.1. Next Generation Sequencing
8.6.1.1. Illumina Sequencing
8.6.1.2. Ion Torrent Sequencing
8.6.2. Polymerase Chain Reaction
8.6.2.1. Conventional Polymerase Chain Reaction
8.6.2.2. Real Time Polymerase Chain Reaction
9. Fungal Infections Diagnosis Market, by End User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals & Clinics
9.4. Research Institutes
10. Fungal Infections Diagnosis Market, by Specimen Type
10.1. Introduction
10.2. Blood
10.3. Cerebrospinal Fluid
10.4. Sputum
10.5. Tissue
10.6. Urine
11. Fungal Infections Diagnosis Market, by Pathogen Type
11.1. Introduction
11.2. Aspergillosis
11.3. Candidiasis
11.4. Cryptococcosis
11.5. Dermatophytosis
11.6. Mucormycosis
12. Fungal Infections Diagnosis Market, by Testing Mode
12.1. Introduction
12.2. Laboratory Testing
12.3. Point of Care Testing
12.4. Research Use Only
13. Americas Fungal Infections Diagnosis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Fungal Infections Diagnosis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Fungal Infections Diagnosis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Roche Holding AG
16.3.3. Abbott Laboratories
16.3.4. bioMérieux SA
16.3.5. Becton, Dickinson and Company
16.3.6. Bruker Corporation
16.3.7. DiaSorin S.p.A.
16.3.8. QIAGEN N.V.
16.3.9. Siemens Healthineers AG
16.3.10. Fujirebio Holdings, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET MULTI-CURRENCY
FIGURE 2. FUNGAL INFECTIONS DIAGNOSIS MARKET MULTI-LANGUAGE
FIGURE 3. FUNGAL INFECTIONS DIAGNOSIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 70. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 71. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 72. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 73. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 74. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 75. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 81. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 84. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 132. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 134. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 135. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 136. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 139. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 140. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 142. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 145. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 146. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 160. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 162. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 163. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 164. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 165. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 166. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 168. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 169. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 172. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 174. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 175. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 176. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 179. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 212. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 214. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 215. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 216. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 218. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 219. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 230. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 231. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 232. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 233. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 234. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 235. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 236. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 238. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 239. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 242. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 245. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 246. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 248. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 249. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 272. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 274. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 275. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 276. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 278. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 279. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 280. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 282. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 284. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 285. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 286. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 288. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 289. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2030 (USD MILLION)
TABLE 300. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 301. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2030 (USD MILLION)
TABLE 302. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 304. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 305. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 306. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Fungal Infections Diagnosis market report include:
  • Thermo Fisher Scientific Inc.
  • Roche Holding AG
  • Abbott Laboratories
  • bioMérieux SA
  • Becton, Dickinson and Company
  • Bruker Corporation
  • DiaSorin S.p.A.
  • QIAGEN N.V.
  • Siemens Healthineers AG
  • Fujirebio Holdings, Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.35 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Microbiology Diagnostic Devices Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Microbiology Diagnostic Devices Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 156 Pages
  • Global
From
EUR$4,250USDGBP
Microbiology Diagnostic Devices and Equipment Market Report 2025 - Product Image

Microbiology Diagnostic Devices and Equipment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
EUR$4,490USDGBP
Uterine Cancer Therapeutics & Diagnostics Market by Treatment Type, Diagnostic Product Type, Diagnostic Technology, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030 - Product Image

Uterine Cancer Therapeutics & Diagnostics Market by Treatment Type, Diagnostic Product Type, Diagnostic Technology, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Rare Disease Diagnostics: Technologies and Global Markets - Product Image

Rare Disease Diagnostics: Technologies and Global Markets

  • Report
  • 131 Pages
  • Global
From
EUR$4,650USDGBP
Immunochemistry Diagnostic Devices and Equipment Market Report 2025 - Product Image

Immunochemistry Diagnostic Devices and Equipment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
EUR$4,490USDGBP
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more